Skip to content

Chicago Jury Finds AbbVie Fraudulently Marketed AndroGel to Injured Oregon Man; Awards $150 Million in Punitive Damages

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug. “This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. […]

July 24, 2017

Via PRNewswire — A federal jury in Chicago found that AbbVie Inc. committed fraud in its marketing of its testosterone replacement therapy drug, AndroGel, awarding $150 million in punitive damages to an Oregon plaintiff, Jesse Mitchell, who suffered a heart attack after using the drug.

“This is a great result for the Mitchell family and all the other victims of AbbVie’s fraudulent conduct. Today, this jury sent a clear message. AbbVie, hopefully, hears it,” said MDL co-lead counsel Chris Seeger.  Mr. Mitchell is one of more than 4,000 plaintiffs who have sued AbbVie Inc. in the federal multidistrict litigation, In re: Testosterone Replacement Therapy Products Liability Litigation, case number 1:14-cv-01748, before Judge Matthew Kennelly in the U.S. District Court for the Northern District of Illinois. Mr. Mitchell claimed that AbbVie fraudulently misled doctors and patients about the drug’s benefits and risks—in particular, cardiovascular risks—when marketing the drug. The jury deliberated for 4 hours before reaching its verdict.  Partner Dave Buchanan, a member of the Mitchell trial team, commented, “For years before Jesse took AndroGel, AbbVie promoted unproven benefits and falsely assured doctors and patients about the safety of the drug.  The consequences of those acts are serious and real—facts that weren’t lost on this jury.”

Mr. Mitchell was represented by Troy Rafferty of Levin Papantonio, lead, David Buchanan of Seeger WeissBill Robins of Robins Cloud, Stephanie O’Connor of Douglas & London, and David Diamond of Goldberg & Osborne. The case is Mitchell et al. v. AbbVie Inc. et al., case number 1:14-cv-09178.

Notwithstanding claims relating to this product, the drug/medical device remains approved by the U.S. FDA.

Related News

March 14, 2023
Seeger Weiss Obtains $10 Million Settlement In Whistleblower Lawsuit Against Medical Device Company Stimwave

New York, NY– Today, the Department of Justice announced a $10 million settlement with Florida-based medical device company Stimwave, and a criminal indictment charging former CEO Laura Perryman in connection with a scheme to create and sell a non-functioning dummy medical device for implantation into patients suffering from chronic pain.  The scheme resulted in millions […]

Read More
February 28, 2023
Eleven Seeger Weiss Partners Selected For Lawdragon 500 Leading Plaintiff Consumer Lawyers List

Seeger Weiss is proud to announce that eleven of the firm’s partners were selected for Lawdragon 500 Leading Plaintiff Consumer Lawyers list for 2023. This list celebrates attorneys who are “tenacious advocates and dogged pursuers of justice,” a description fitting for these accomplished members of the Seeger Weiss team. Founding partners Chris Seeger and Stephen […]

Read More
February 9, 2023
Former NFL Players File Class Action Lawsuit Against NFL Disability Plans, Board, Commissioner Roger Goodell For Systemic Bias Against Disabled Players

New data suggest “neutral” NFL-hired doctors who deny more claims receive higher compensation. Baltimore, MD – Former NFL players today filed a class action lawsuit against The NFL Player Disability & Survivor Benefit Plan and NFL Player Disability & Neurocognitive Benefits Plan (the Plan), the Disability Board that administers the Plan, and each of the […]

Read More